Adipo Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Adipo Therapeutics was founded to develop a treatment for obesity and type 2 diabetes (T2D) through localized, sustained, nanoparticle-delivered Notch inhibition to induce adipose browning. Browning transforms energy storing white fat into energy burning brown fat, causing weight loss and glucose lowering. Adipo expects this patented therapy to be widely accepted by physicians treating patients with T2D, where injectable treatment is well established. Adipo validated the proof-of-principal in preclinical obesity models, demonstrating browning, weight loss and glucose lowering. Adipo in funded by an angel investor, Purdue Research Foundation, Elevate Ventures and an NIH SBIR grant. Adipo plans to develop its asset through proof-of-concept in patients (Phase 2 FDA clinical trial) followed by licensing to a pharmaceutical company in diabetes. Adipo Therapeutics is led by a team experienced in developing, registering, manufacturing and commercializing products in diabetes and obesity.
Company Type:
Company Website:
Company HQ State:
Indiana
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Adipo Notch-Inhibitor Nanoparticle
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Adipo Therapeutics